Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon With Concurrent Radiation and Temozolomide in Newly Diagnosed Glioblastoma
2024-512954-96-00Phase 2Completed
- Sponsor
- Cantex Pharmaceuticals, Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azeliragon in glioblastoma (GBM), sponsored by Cantex Pharmaceuticals, Inc. Started May 2024; status: completed.
02
Drugs
azeliragon
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-512954-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512954-96-00.